Inmune Stock News

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced presen

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a co

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, CEO

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced publication of an invited review

By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Testing DN-TNF Platform as Treatment for COVID-19 On April 20, 2020, INmune Bio, Inc. (NASDAQ:INMB) announced that th

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States

Maxim Group analyst Jason McCarthy assigned a Buy rating to Inmune Bio (INMB) today and set a price target of $13.00. The company's shares closed last

Maxim Group analyst Jason McCarthy assigned a Buy rating to Inmune Bio ( INMB – Research Report ) today and set a price target of $13.00 . The company’s shares closed last Tuesday at $4.27. Accord

Trade CFDs on Indices, cryptocurrencies, metals, forex, stocks, and commodities on a single platform Choosing the right brokerage firm is as crucial as choosing trading assets. If your decision is rig

INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the initiation of a therapeutic p

Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to...

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX